Andrew Lloyd

19.7k total citations · 3 hit papers
175 papers, 13.2k citations indexed

About

Andrew Lloyd is a scholar working on Economics and Econometrics, General Health Professions and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew Lloyd has authored 175 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Economics and Econometrics, 25 papers in General Health Professions and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew Lloyd's work include Health Systems, Economic Evaluations, Quality of Life (75 papers), Economic and Environmental Valuation (14 papers) and Economic and Financial Impacts of Cancer (12 papers). Andrew Lloyd is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (75 papers), Economic and Environmental Valuation (14 papers) and Economic and Financial Impacts of Cancer (12 papers). Andrew Lloyd collaborates with scholars based in United Kingdom, United States and Switzerland. Andrew Lloyd's co-authors include Paul Kind, Michael Herdman, Claire Gudex, Xavier Badı́a, M.H.M. Janssen, Gouke J. Bonsel, David Parkin, A. Simon Pickard, Lisa A. Prosser and John F. P. Bridges and has published in prestigious journals such as Journal of Clinical Oncology, Social Science & Medicine and British Journal of Cancer.

In The Last Decade

Andrew Lloyd

162 papers receiving 13.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

2011 6.1k citations Michael Herdman, Claire Gudex et al. Quality of Life Research profile →
Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

2011 1.4k citations Andrew Lloyd, Lisa A. Prosser et al. Value in Health profile →
Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

2012 1.4k citations Andrew Lloyd, Paul Kind et al. Value in Health profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Andrew Lloyd	4.3k	2.5k	1.7k	1.4k	1.4k	175	13.2k
Xavier Badı́a	3.7k 0.9×	2.9k 1.2×	2.4k 1.4×	1.2k 0.9×	842 0.6×	189	16.3k
Claire Gudex	3.6k 0.8×	2.6k 1.0×	1.7k 1.0×	690 0.5×	629 0.4×	71	11.5k
Jan J.V. Busschbach	4.5k 1.0×	2.7k 1.1×	2.4k 1.4×	742 0.5×	661 0.5×	364	15.3k
Gouke J. Bonsel	4.1k 1.0×	3.6k 1.5×	2.7k 1.6×	1.5k 1.0×	901 0.6×	296	21.0k
Michael Herdman	3.4k 0.8×	2.6k 1.1×	1.4k 0.8×	668 0.5×	559 0.4×	60	11.7k
Paul Kind	6.9k 1.6×	4.4k 1.8×	2.5k 1.4×	936 0.7×	1.0k 0.7×	146	17.9k
Johan L. Severens	2.4k 0.6×	2.0k 0.8×	976 0.6×	1.7k 1.2×	806 0.6×	259	10.7k
A. Mark Fendrick	3.3k 0.8×	2.2k 0.9×	2.5k 1.5×	1.7k 1.2×	1.5k 1.1×	359	11.7k
Stephen J. Walters	1.7k 0.4×	2.0k 0.8×	2.4k 1.4×	1.0k 0.7×	967 0.7×	276	12.4k
C. Daniel Mullins	3.1k 0.7×	2.2k 0.9×	1.3k 0.7×	1.2k 0.8×	1.5k 1.1×	361	10.7k

Countries citing papers authored by Andrew Lloyd

Since Specialization

Citations

This map shows the geographic impact of Andrew Lloyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Lloyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Lloyd more than expected).

Fields of papers citing papers by Andrew Lloyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Lloyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Lloyd. The network helps show where Andrew Lloyd may publish in the future.

Co-authorship network of co-authors of Andrew Lloyd

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Lloyd. A scholar is included among the top collaborators of Andrew Lloyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Lloyd. Andrew Lloyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matter, E. Ann, et al.. (2025). The Burden of Adult X-Linked Hypophosphatemia on Carers and Family Members: A Mixed-Methods Study. Journal of health economics and outcomes research. 162–170.

Parkin, David, et al.. (2025). Uncertainty around Health State Values Used in Cost-Effectiveness Analysis: How It Arises and How to Deal with It. Medical Decision Making. 46(2). 130–143.

Chua, Gin Nie, et al.. (2025). Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States. Health and Quality of Life Outcomes. 23(1). 7–7.

Ciaccio, Christina E., et al.. (2024). Living with and Caring for People with Multiple Food Allergies: A Qualitative Study. Patient Preference and Adherence. Volume 18. 1949–1960. 4 indexed citations

Schmid, Peter, Heather L. McArthur, Baojun Xu, et al.. (2024). LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial. Annals of Oncology. 35. S1212–S1213. 5 indexed citations

Aggio, Daniel, et al.. (2024). Estimation of health utility values for alopecia areata. Quality of Life Research. 33(6). 1581–1592. 1 indexed citations

Al‐Janabi, Hareth, Werner Brouwer, John Cullinan, et al.. (2023). Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force. PharmacoEconomics. 42(3). 343–362. 17 indexed citations

Santi, Irene, Andrew Lloyd, Claudia Hastedt, & Matthijs Versteegh. (2023). Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale. Advances in Therapy. 40(9). 4060–4073. 1 indexed citations

Lloyd, Andrew, Daniel Aggio, Ernest H. Law, & Thomas M Price. (2023). CO149 Does the EQ-5D Measure the Full Impact of Alopecia Areata on Patients' Health Related Quality of Life?. Value in Health. 26(12). S41–S41.

10.

Hobart, Jeremy, Tanuja Chitnis, Jiwon Oh, et al.. (2023). Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection. Multiple Sclerosis and Related Disorders. 76. 104788–104788. 2 indexed citations

11.

Chitnis, Tanuja, Birgit Bauer, Giampaolo Brichetto, et al.. (2022). Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?. Multiple Sclerosis Journal - Experimental Translational and Clinical. 8(2). 3090468842–3090468842. 6 indexed citations

12.

Lo, Siu Hing, et al.. (2021). Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. PharmacoEconomics - Open. 6(1). 105–121. 6 indexed citations

13.

Lo, Siu Hing, Andrew Lloyd, Shuayb Elkhalifa, Zlatko Sisic, & Floortje van Nooten. (2021). Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. PharmacoEconomics - Open. 6(2). 231–239. 2 indexed citations

14.

Lo, Siu Hing, et al.. (2021). Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. PharmacoEconomics. 40(S1). 91–102. 7 indexed citations

15.

Lo, Siu Hing, Rohini Sharma, Charlotte Costentin, et al.. (2021). Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study. Future Oncology. 17(32). 4275–4287. 16 indexed citations

16.

Lo, Siu Hing, et al.. (2021). Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries. PharmacoEconomics. 40(S1). 103–115. 5 indexed citations

17.

Dewilde, Sarah, Lieven Annemans, Andrew Lloyd, et al.. (2019). The combined impact of dependency on caregivers, disability, and coping strategy on quality of life after ischemic stroke. Health and Quality of Life Outcomes. 17(1). 31–31. 33 indexed citations

18.

Shingler, S.L., et al.. (2013). Utilities for advanced basal cell carcinoma. Journal of Medical Economics. 16(6). 777–783. 15 indexed citations

19.

Herdman, Michael, Claire Gudex, Andrew Lloyd, et al.. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 20(10). 1727–1736. 6138 indexed citations breakdown →

20.

Burns, Ethel, et al.. (2000). An Investigation into the Use of Aromatherapy in Intrapartum Midwifery Practice. The Journal of Alternative and Complementary Medicine. 6(2). 141–147. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact